Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis

Tundra lists 1 HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07203729

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis. Participants will take Trastuzumab Rezetecan every three weeks, until disease progression or intolerable toxicity.

Gender: FEMALE

Ages: 18 Years - 75 Years

Updated: 2026-03-16

1 state

HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis